Interní Med. 2007; 9(2): 99-101

Malígny feochromocytóm

MUDr. Barbora Desatová2, MUDr. Eva Hirnerová PhD2, doc. MUDr. Izabela Makaiová CSc1, doc. MUDr. Andrej Dukát CSc., FESC2, MUDr. I. Vranka2, RNDr. Soňa Kováčová CSc1, MUDr. Jaroslav Veselý1
1 Klinika nukleárnej medicíny LF UK a OÚSA, Bratislava
2 II. interná klinika LF UK, FN Bratislava

Malígny feochromocytóm je zriedkavý neuroendokrinný nádor s vysokou mortalitou. Jediným dôkazom jeho malignity je prítomnosť metastáz, čo znamená, že v prípade ich neprítomnosti nie je možné s istotou odlíšiť malígny feochromocytóm od benígneho (16). V článku prezentujeme kazuistiku 55-ročnej pacientky s nevyrovnanými hodnotami tlaku krvi (TK) a výraznými subjektívnymi ťažkosťami, u ktorej bol v rámci pátrania po príčine sekundárnej hypertenzie diagnostikovaný malígny feochromocytóm so vzdialenými metastázami. Ich prítomnosť sa nám podarilo dokázať použitím kombinácie laboratórnych a viacerých zobrazovacích metód, predovšetkým vyšetrením hladiny chromogranínu A a neurón špecifickej enolázy (NSE) v sére, CT vyšetrením, scintigrafiou skeletu, celotelovou scintigrafiou distribúcie 123I - metajodobenzylguanidínu (123I-MIBG) a pozitrónovou emisnou tomografiou (PET) s použitím 18-fluorodeoxyglukózy (18-FDG).

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Desatová B, Hirnerová E, Makaiová I, Dukát A, Vranka MI, Kováčová S, Veselý J. Malígny feochromocytóm. Interní Med. 2007;9(2):99-101.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 2000; 86 (5): 858-865. Go to original source...
    2. Balažovjech I. Feochromocytóm. In: Balažovjech I. Artériová hypertenzia. Martin: Vydavateľstvo Osveta 1999: 340-361.
    3. Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991; 12 (2): 181-187. Go to original source... Go to PubMed...
    4. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer 2004; 11 (3): 423-436. Go to original source... Go to PubMed...
    5. Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004; 1018: 495-504. Go to original source... Go to PubMed...
    6. Lam MG, Lips CJ, Jager PL, et al. Repeated (131)metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005; 90 (10): 5888-5895. Go to original source... Go to PubMed...
    7. Lángoš J, Blažíček P. Nádory sympatikoadrenálneho systému. In: Keere A, Langer P, Klimeš I, et al. Všeobecná a klinická endokrinológia. Bratislava: Academic Electronic Press s.r.o. 2004: 412-422.
    8. Lenz T, Gossmann J, Schulte KL, et al. Diagnosis of pheochromocytoma. Clin Lab 2002; 48 (1-2): 5-18. Go to PubMed...
    9. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20 (11): 648-658. Go to original source... Go to PubMed...
    10. Makaiová I, Balažovjech I, Hasík E, et al. Gamagrafické zobrazenie feochromocytómu 131I-metajodobenzylguanidínom. Bratisl. Lek. Listy 1989, 9: 631-636.
    11. Mamede M, Carrasquillo JA, Chen CC, et al. Discordant localization of 2-(18F)-fluoro-2deoxy-D-glucose in 6-(18F)-fluorodopamineand {(123)I}-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 2006; 27 (1): 31-36. Go to original source... Go to PubMed...
    12. Manger WM, Eisenhofer G. Pheochromocytoma: Diagnosis and management update. Curr Hypertens Rep. 2004; 6 (6): 477-484. Go to original source... Go to PubMed...
    13. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine {(131)I-mIBG}. Clin Endocrinol (Oxf) 2001; 55 (1): 47-60. Go to original source... Go to PubMed...
    14. Pederson LC, Lee JE. Pheochromocytoma. Curr Treat Options Oncol 2003; 4 (4): 329-337. Go to original source... Go to PubMed...
    15. Syversen U, Heide LS, Waldum HL. Chromogranin A in blood - useful tumor marker. Tidsskr Nor Laegeforen 1997; 117 (26): 3810-3811. Go to PubMed...
    16. Zarnegar R, Kebebew, Duh QY, et al. Malignant pheochromocytoma. Surg Oncol Clin N Am 2006; 15 (3): 555-571. Go to original source... Go to PubMed...
    17. http://www.labor-limbach.de/index.php?id=229.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.